Brief: GSK Says US FDA To Review Jemperli For Rectal Cancer
24/08/2026 07:16
BRIEF-GSK Says US FDA To Review Jemperli For Rectal Cancer Aug 24 (Reuters) - GSK plc GSK.L:
GSK PLC - US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER
GSK - JEMPERLI APPLICATION ACCEPTED UNDER PROJECT ORBIS FOR COORDINATED INTERNATIONAL REVIEW
GSK - JEMPERLI APPLICATION ELIGIBLE FOR EXPEDITED REVIEW VIA NATIONAL PRIORITY VOUCHER PROGRAM
GSK - AZUR-1 DATA SHOWS SIGNIFICANT PROPORTION WITH NO DETECTABLE CANCER AFTER ONE YEAR
GSK - FDA HAS ASSIGNED A PDUFA ACTION DATE OF FEBRUARY 2027.
Source text: ID:nRSX7605Ra
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))